Mario Boccadoro

16PUBLICATIONS
113CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersMedical infection agents (incl. prions)Tissue engineering
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Feb 18, 2025
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma.

Martin F Kaiser, Pieter Sonneveld, David A Cairns

|Jul 19, 2024
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma.

Bachisio Ziccheddu, Claudia Giannotta, Mattia D'Agostino

|Jun 07, 2024
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells.

Mattia D'Agostino, Delia Rota-Scalabrini, Angelo Belotti

|Dec 07, 2023
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.

Elias K Mai, Thomas Hielscher, Uta Bertsch

|May 04, 2023
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).

Evangelos Terpos, Pellegrino Musto, Monika Engelhardt

|Jun 06, 2022
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.

Luca Bertamini, Stefania Oliva, Delia Rota-Scalabrini

Pageof 3

Frequent Collaborators

6 joint publications

Francesca Gay

5 joint publications

Pieter Sonneveld

5 joint publications

Paolo Corradini

5 joint publications

Alessandra Larocca